CFTR and cystic fibrosis: (i) Performing a two-step approach, where in the first step, novel CFTR modulators/combinations were tested on organoids from over 500 European and Israeli CF patients with rare CFTR mutations to identify patients predicted to clinically benefit from these treatments. The second step will evaluate the predicted clinical effect in subjects identified by their organoid response